Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
Type:
Grant
Filed:
September 6, 2001
Date of Patent:
September 26, 2006
Assignee:
Biogen Idec MA Inc.
Inventors:
Christine M. Ambrose, Jeffrey S. Thompson
Abstract: The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.
Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
Type:
Grant
Filed:
April 11, 1994
Date of Patent:
May 14, 1996
Assignee:
Vertex Pharmaceuticals, Incorporated
Inventors:
David M. Armistead, Joshua S. Boger, Harold V. Meyers, Jeffrey O. Saunders, Roger D. Tung
Abstract: Methods of and compositions for early diagnosis, monitoring and treatment of osteoarthritis using monoclonal antibodies which specifically recognize antigenic determinants on atypical chondroitin sulfate/dermatan sulfate glycosaminoglycan chains in body tissues and fluids, which determinants are markers of osteoarthritis.
Abstract: This invention relates to interleukin inhibitors (IL-1 INHs) that selectively inhibit interleukin 1 activity. The invention also relates to processes for purifying such IL-1 INHs from urine and for producing such IL-1 INHs by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the inhibitors, and to methods of treatment and compositions characterized by such IL-1 INHs. These methods and agents are useful in immunosuppressive and anti-inflammatory applications and therapies.
Type:
Grant
Filed:
December 1, 1992
Date of Patent:
October 25, 1994
Assignee:
Biogen Inc.
Inventors:
Jean M. Dayer, Philippe L. Seckinger, Gonzalo J. Mazzei, Alan R. Shaw
Abstract: Linear and cyclic peptides of the E1 and C protein of the rubella virus are disclosed. These peptides and analogues, mixtures and combinations of them are useful in detecting and quantifying antibodies raised against the rubella virus. They are also useful in raising antibodies to the rubella virus for use in the diagnosis of and protection against rubella viral infections.
Type:
Grant
Filed:
August 23, 1989
Date of Patent:
November 17, 1992
Assignee:
IAF Biochem International Inc.
Inventors:
Martial Lacroix, Maan Zrein, Gervais Dionne
Abstract: Methods and compositions for preventing or treating human immunodeficiency virus (HIV) infections characterized by 2-substituted-5-substituted-1,3-oxathiolanes.
Abstract: Thioacylating reagents are provided for the introduction of thioamide bonds into growing peptides represented by the structure: ##STR1## where the substituents are disclosed herein. Intermediate precursors for preparing these thioacylating reagents are also provided. A process for preparing the thioacylating reagents and the intermediate precursors is further provided.
Type:
Grant
Filed:
August 4, 1989
Date of Patent:
August 11, 1992
Assignee:
BioChem Pharma Inc.
Inventors:
Bernard Belleau, deceased, Denis Brillon, Gilles Sauve, Boulos Zacharie
Abstract: This invention relates to the immunotherapeutic treatment of allergies. More particularly, this invention relates to a process for treating allergies by administering to a mammal a pharmaceutically effective amount of gamma interferon.
Type:
Grant
Filed:
April 30, 1987
Date of Patent:
June 16, 1992
Assignee:
Biogen, Inc.
Inventors:
Anthony J. Pinching, Jacqueline M. Parkin
Abstract: Methods and compositions for preventing or treating human immunodeficiency virus (HIV) infections characterized by 2-substituted-5-substituted-1,3-oxathiolanes.